DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactEconomy

Teva Releases Q3 2026 Aide Memoire

Yahoo Finance Singapore 11 hrs ago·23 Sept 2026, 8:45 pm

Economy Yahoo Finance Singapore

Teva Pharmaceutical Industries has released its third-quarter 2026 aide memoire, providing investors with an early look at its operational performance and strategic outlook. This document outlines key business metrics and management's current thinking on market conditions.

For the broader market, this update is significant as it offers a preview of the drugmaker's progress in navigating a competitive landscape. Investors will be closely watching for any shifts in guidance regarding revenue growth, cost management, or pipeline developments.

Moving forward, market participants should focus on the specific details regarding the company's earnings trajectory and its response to evolving regulatory environments. This information will be crucial for assessing the company's ability to maintain its market position and deliver long-term value.

Excerpt from Yahoo Finance Singapore

TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the "Investors" page on its website. Teva has compiled this document with public information that was previously provided by…

Read the original at Yahoo Finance Singapore